Emergent BioSolutions (EBS) Total Liabilities (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Total Liabilities of $797.3 million for Q1 2026, down 8.71% year-over-year from $873.4 million in Q1 2025, and little changed quarter-over-quarter from $796.0 million in Q4 2025.
Emergent BioSolutions (EBS) Total Liabilities (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Total Liabilities history runs 17 years deep, the most recent figure standing at $797.3 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 8.71% year-over-year to $797.3 million; the TTM figure through Mar 2026 stood at $797.3 million (down 8.71% YoY), while the FY2025 annual figure was $796.0 million, down 12.23% from the prior year.
- Total Liabilities for Q1 2026 stood at $797.3 million, roughly flat from $796.0 million in the prior quarter.
- The five-year high for Total Liabilities was $1.8 billion in Q4 2022, with the low at $796.0 million in Q4 2025.
- The 5-year median for Total Liabilities is $1.1 billion (2024), against an average of $1.1 billion.
- The sharpest annual moves came in 2023 and 2024: Total Liabilities jumped 44.98% in 2023, then tumbled 34.77% in 2024.
- Emergent BioSolutions' Total Liabilities stood at $1.8 billion in 2022, then tumbled by 34.0% to $1.2 billion in 2023, then fell by 22.74% to $906.9 million in 2024, then declined by 12.23% to $796.0 million in 2025, then gained by 0.16% to $797.3 million in 2026.
- Business Quant data shows EBS's Total Liabilities at $797.3 million in Q1 2026, $796.0 million in Q4 2025, and $878.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.12 Bn |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 775.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 775.40 Mn |
| Mar 31, 2026 | 797.30 Mn |
| Dec 31, 2025 | 796.00 Mn |
| Sep 30, 2025 | 878.50 Mn |
| Jun 30, 2025 | 880.90 Mn |
| Mar 31, 2025 | 873.40 Mn |
| Dec 31, 2024 | 906.90 Mn |
| Sep 30, 2024 | 969.40 Mn |
| Jun 30, 2024 | 1.13 Bn |
| Mar 31, 2024 | 1.14 Bn |
| Dec 31, 2023 | 1.17 Bn |
| Sep 30, 2023 | 1.20 Bn |
| Jun 30, 2023 | 1.22 Bn |
| Mar 31, 2023 | 1.75 Bn |
| Dec 31, 2022 | 1.78 Bn |
| Sep 30, 2022 | 1.46 Bn |
| Jun 30, 2022 | 1.22 Bn |
| Mar 31, 2022 | 1.21 Bn |
| Dec 31, 2021 | 1.35 Bn |
| Sep 30, 2021 | 1.34 Bn |